Post reply

The message has the following error or errors that must be corrected before continuing:
Warning: this topic has not been posted in for at least 365 days.
Unless you're sure you want to reply, please consider starting a new topic.
Other options
Verification:
Please leave this box empty:
Type the letters shown in the picture
Listen to the letters / Request another image

Type the letters shown in the picture:
Please spell spammer backwards:
Spell the answer to 6 + 7 =:
Shortcuts: ALT+S post or ALT+P preview

Topic summary

Posted by ninjaroll
 - April 21, 2015, 01:30:59 PM
http://www.wsj.com/articles/teva-offers-to-buy-mylan-for-82-a-share-1429620984

The part we care about.  Not that I truly understand the implication of Teva developing a generic or the merger of pharmaceuticals in general.

QuoteFor Teva and Mylan in recent years, sales of brand-name products have helped cushion the blows. Teva's revenue and profit have been boosted by a brand-name multiple-sclerosis drug called Copaxone, while Mylan has benefited from the branded EpiPen emergency treatment for allergic reactions.

But each company is facing competition for the key moneymakers. Just last week, Novartis AG and partner Momenta Pharmaceuticals Inc. won U.S. regulatory approval to sell a generic version of Teva's Copaxone. Meantime, Teva is among the companies trying to develop a generic EpiPen.